Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers

Trial Profile

A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs ARO AAT (Primary)
  • Indications Alpha 1-antitrypsin deficiency
  • Focus Adverse reactions; First in man
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2018 According to an Arrowhead Pharmaceuticals media release, data from this study were presented at the The Liver Meeting 2018, the Annual Meeting of the American Association for the Study of Liver Disease.
    • 01 Nov 2018 According to an Arrowhead Pharmaceuticals media release, data from this study will be presented at the The Liver Meeting 2018, the Annual Meeting of the American Association for the Study of Liver Disease.
    • 11 Oct 2018 Results presented in an Arrowhead Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top